{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:29:33Z","timestamp":1785925773791,"version":"3.56.0"},"reference-count":91,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Primary hyperoxalurias (PHs) are rare autosomal recessive disorders characterized by overproduction of oxalate, a metabolic end product that readily forms calcium oxalate crystals. Excess hepatic oxalate leads to recurrent kidney stones, nephrocalcinosis, and progressive renal injury, often culminating in end-stage kidney disease (ESKD). Once renal clearance declines, systemic oxalate accumulation can cause multisystem deposition. PH encompasses three types\u2014PH1, PH2, and PH3\u2014caused by deficiencies in the hepatic enzymes AGT, GRHPR, and HOGA1, respectively, resulting in accumulation of glyoxylate and subsequent oxalate overproduction. Clinical presentation varies from infantile oxalosis to adult-onset recurrent nephrolithiasis, with PH1 generally being the most severe. Diagnosis relies on urinary oxalate measurements, plasma oxalate in advanced chronic kidney disease, urinary metabolite profiling, imaging, and genetic testing. Management includes hyperhydration, citrate supplementation, pyridoxine for responsive PH1 patients, dialysis and transplantation when required, while RNA interference therapies targeting glycolate oxidase or LDHA have demonstrated substantial biochemical efficacy in PH1 and represent promising emerging therapeutic options, although long-term clinical outcome data remain limited and broader applicability to other PH types is still under investigation. Future strategies focus on modulating intestinal oxalate absorption, gut microbiome therapies, oxalate-degrading enzymes, and novel gene-editing approaches. Early diagnosis and individualized management are critical to prevent kidney injury and systemic oxalosis. In this review, we summarize the genetic, biochemical, and clinical features of PH and discuss current and emerging therapeutic strategies.<\/jats:p>","DOI":"10.3390\/jcm15030940","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:21:40Z","timestamp":1769505700000},"page":"940","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Approaches and Emerging Therapeutic Horizons in Primary Hyperoxaluria"],"prefix":"10.3390","volume":"15","author":[{"given":"Ruth","family":"Mart\u00ednez-Galindo","sequence":"first","affiliation":[{"name":"Nephrology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3907-499X","authenticated-orcid":false,"given":"Mar\u00eda","family":"Campuzano-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Urology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afroditi","family":"Konstantouli","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1902-1333","authenticated-orcid":false,"given":"Mar\u00eda Del Pilar","family":"Aguilar-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Urology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio Mainez","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Urology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Abad-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Urology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-4701","authenticated-orcid":false,"given":"Amir","family":"Shabaka","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Cansino","sequence":"additional","affiliation":[{"name":"Urology Department, Hospital Universitario La Paz, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary Hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1172\/JCI63679","article-title":"Calcium Oxalate Crystals Induce Renal Inflammation by NLRP3-Mediated IL-1\u03b2 Secretion","volume":"123","author":"Mulay","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41585-021-00543-4","article-title":"Perspectives in Primary Hyperoxaluria\u2014Historical, Current and Future Clinical Interventions","volume":"19","author":"Shee","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamainternmed.2018.7980","article-title":"Association of Urinary Oxalate Excretion with the Risk of Chronic Kidney Disease Progression","volume":"179","author":"Waikar","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1093\/ndt\/gfs320","article-title":"Primary Hyperoxaluria Type 1, a Too Often Missed Diagnosis and Potentially Treatable Cause of End-Stage Renal Disease in Adults: Results of the Dutch Cohort","volume":"27","author":"Groothoff","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2014070698","article-title":"Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria","volume":"26","author":"Hopp","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ndt\/10.supp8.3","article-title":"Epidemiology of Primary Hyperoxaluria Type 1","volume":"10","author":"Cochat","year":"1995","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00467-022-05613-2","article-title":"OxalEurope Consortium\/Erknet Guideline Workgroup on Hyperoxaluria Genetic Assessment in Primary Hyperoxaluria: Why It Matters","volume":"38","author":"Mandrile","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"ref_9","unstructured":"Adam, M.P., Bick, S., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Primary Hyperoxaluria Type 1. GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15886","DOI":"10.1038\/s41598-022-17980-9","article-title":"Clinical and Molecular Characterization of Primary Hyperoxaluria in Egypt","volume":"12","author":"Soliman","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_11","unstructured":"Adam, M.P., Bick, S., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Primary Hyperoxaluria Type 2. GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_12","unstructured":"Adam, M.P., Bick, S., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Primary Hyperoxaluria Type 3. GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41581-022-00643-3","article-title":"Oxalate Homeostasis","volume":"19","author":"Ermer","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0022-5347(01)62363-2","article-title":"Glyoxylate Synthesis, and Its Modulation and Influence on Oxalate Synthesis","volume":"160","author":"Holmes","year":"1998","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1055\/s-0030-1265145","article-title":"Metabolism of Fructose to Oxalate and Glycolate","volume":"42","author":"Knight","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2215\/CJN.02760311","article-title":"Primary Hyperoxaluria Type III Gene HOGA1 (Formerly DHDPSL) as a Possible Risk Factor for Idiopathic Calcium Oxalate Urolithiasis","volume":"6","author":"Monico","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajhg.2010.07.023","article-title":"Mutations in DHDPSL Are Responsible for Primary Hyperoxaluria Type III","volume":"87","author":"Belostotsky","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jmb.2006.05.018","article-title":"Structural Basis of Substrate Specificity in Human Glyoxylate Reductase\/Hydroxypyruvate Reductase","volume":"360","author":"Booth","year":"2006","journal-title":"J. Mol. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1042\/BJ20070637","article-title":"Human Wild-Type Alanine:Glyoxylate Aminotransferase and Its Naturally Occurring G82E Variant: Functional Properties and Physiological Implications","volume":"408","author":"Cellini","year":"2007","journal-title":"Biochem. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s004310050649","article-title":"Primary Hyperoxaluria Type 2","volume":"156","author":"Kemper","year":"1997","journal-title":"Eur. J. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ki.2009.32","article-title":"The Primary Hyperoxalurias","volume":"75","author":"Hoppe","year":"2009","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.ajkd.2007.08.027","article-title":"Primary Hyperoxaluria: Clinical Course, Diagnosis, and Treatment After Kidney Failure","volume":"51","author":"Raju","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"i23","DOI":"10.1093\/ckj\/sfab231","article-title":"Primary Hyperoxaluria: The Pediatric Nephrologist\u2019s Point of View","volume":"15","author":"Garrelfs","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.kint.2019.11.023","article-title":"Clinical Features of Genetically Confirmed Patients with Primary Hyperoxaluria Identified by Clinical Indication versus Familial Screening","volume":"97","author":"Sas","year":"2020","journal-title":"Kidney Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ejhg.2012.139","article-title":"Novel Findings in Patients with Primary Hyperoxaluria Type III and Implications for Advanced Molecular Testing Strategies","volume":"21","author":"Beck","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"gfaa142.P0173","DOI":"10.1093\/ndt\/gfaa142.P0173","article-title":"P0173CHRONIC KIDNEY DISEASE IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 3 (PH 3)\u2014A LITERATURE META-ANALYSIS","volume":"35","author":"Hoppe","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","article-title":"Clinical Practice Recommendations for Primary Hyperoxaluria: An Expert Consensus Statement from ERKNet and OxalEurope","volume":"19","author":"Groothoff","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1007\/s00467-024-06328-2","article-title":"Diagnosis and Management of Primary Hyperoxalurias: Best Practices","volume":"39","author":"Michael","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/clinchem\/30.8.1339","article-title":"Factors Affecting Measurement of Urinary Oxalate","volume":"30","author":"Mazzachi","year":"1984","journal-title":"Clin. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/ki.2014.298","article-title":"Nephrocalcinosis Is a Risk Factor for Kidney Failure in Primary Hyperoxaluria","volume":"87","author":"Tang","year":"2015","journal-title":"Kidney Int."},{"key":"ref_31","unstructured":"Vaidya, S.R., Yarrarapu, S.N.S., and Aeddula, N.R. (2025). Nephrocalcinosis. StatPearls, StatPearls Publishing."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2214\/ajr.146.2.395","article-title":"Radiological Aspects of Primary Hyperoxaluria","volume":"146","author":"Day","year":"1986","journal-title":"Am. J. Roentgenol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2015.07.040","article-title":"EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis","volume":"69","author":"Sarica","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clinimag.2018.09.009","article-title":"Imaging Features of Primary Hyperoxaluria","volume":"52","author":"Rootman","year":"2018","journal-title":"Clin. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7326\/0003-4819-93-1-36","article-title":"Evidence Justifying a High Fluid Intake in Treatment of Nephrolithiasis","volume":"93","author":"Pak","year":"1980","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2014.10.029","article-title":"Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: EAU Guidelines","volume":"67","author":"Skolarikos","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"p31","DOI":"10.1159\/000080261","article-title":"Clinical Value of Crystalluria and Quantitative Morphoconstitutional Analysis of Urinary Calculi","volume":"98","author":"Daudon","year":"2004","journal-title":"Nephron Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00864405","article-title":"Management of Primary Hyperoxaluria: Efficacy of Oral Citrate Administration","volume":"7","author":"Leumann","year":"1993","journal-title":"Pediatr. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ki.2009.237","article-title":"Effect of Conservative Treatment on the Renal Outcome of Children with Primary Hyperoxaluria Type 1","volume":"76","author":"Fargue","year":"2009","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s11255-018-1939-1","article-title":"Metabolic Profile and Impact of Diet in Patients with Primary Hyperoxaluria","volume":"50","author":"Siener","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/ki.2008.63","article-title":"[13C2]Oxalate Absorption in Children with Idiopathic Calcium Oxalate Urolithiasis or Primary Hyperoxaluria","volume":"73","author":"Sikora","year":"2008","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"F409","DOI":"10.1152\/ajprenal.00373.2018","article-title":"Dietary Oxalate and Kidney Stone Formation","volume":"316","author":"Mitchell","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1523-1755.2005.00267.x","article-title":"Pyridoxine Effect in Type I Primary Hyperoxaluria Is Associated with the Most Common Mutant Allele","volume":"67","author":"Monico","year":"2005","journal-title":"Kidney Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199412083312304","article-title":"Results of Long-Term Treatment with Orthophosphate and Pyridoxine in Patients with Primary Hyperoxaluria","volume":"331","author":"Milliner","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2215\/CJN.06820613","article-title":"Vitamin B6 in Primary Hyperoxaluria I: First Prospective Trial after 40 Years of Practice","volume":"9","author":"Kohbrok","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000086358","article-title":"Primary Hyperoxaluria--the German Experience","volume":"25","author":"Hoppe","year":"2005","journal-title":"Am. J. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOU.0000000000000709","article-title":"Future Treatments for Hyperoxaluria","volume":"30","author":"Burns","year":"2020","journal-title":"Curr. Opin. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MNH.0000000000000790","article-title":"New Therapeutics for Primary Hyperoxaluria Type 1","volume":"31","author":"Dejban","year":"2022","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.kint.2019.08.018","article-title":"Patients with Primary Hyperoxaluria Type 2 Have Significant Morbidity and Require Careful Follow-Up","volume":"96","author":"Garrelfs","year":"2019","journal-title":"Kidney Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1: A New RNAi Therapeutic in Infants and Young Children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","article-title":"Safety, Pharmacodynamics, and Exposure-Response Modeling Results from a First-in-Human Phase 1 Study of Nedosiran (PHYOX1) in Primary Hyperoxaluria","volume":"101","author":"Hoppe","year":"2022","journal-title":"Kidney Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: A Pivotal Randomized Study of Nedosiran in Primary Hyperoxaluria Type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.ekir.2025.03.031","article-title":"PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients with Primary Hyperoxaluria Type 1","volume":"10","author":"Lieske","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00467-025-06675-8","article-title":"Nedosiran in Pediatric Patients with PH1 and Relatively Preserved Kidney Function, a Phase 2 Study (PHYOX8)","volume":"40","author":"Sas","year":"2025","journal-title":"Pediatr. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.urology.2021.03.014","article-title":"Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report","volume":"156","author":"Shee","year":"2021","journal-title":"Urology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00240-023-01453-3","article-title":"Nedosiran in Primary Hyperoxaluria Subtype 3: Results from a Phase I, Single-Dose Study (PHYOX4)","volume":"51","author":"Goldfarb","year":"2023","journal-title":"Urolithiasis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"sfae383","DOI":"10.1093\/ckj\/sfae383","article-title":"The Efficacy and Safety of RNA Interference for the Treatment of Primary Hyperoxaluria: A Systematic Review and Meta-Analysis","volume":"18","author":"Yu","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0272-6386(12)80833-X","article-title":"Oxalate Balance Studies in Patients on Hemodialysis for Type I Primary Hyperoxaluria","volume":"19","author":"Marangella","year":"1992","journal-title":"Am. J. Kidney Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s004670050145","article-title":"Oxalate Elimination via Hemodialysis or Peritoneal Dialysis in Children with Chronic Renal Failure","volume":"10","author":"Hoppe","year":"1996","journal-title":"Pediatr. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/sj.ki.5001806","article-title":"Clearance and Removal of Oxalate in Children on Intensified Dialysis for Primary Hyperoxaluria Type 1","volume":"70","author":"Illies","year":"2006","journal-title":"Kidney Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/ndt\/gfh971","article-title":"Oxalate Clearance by Haemodialysis--a Comparison of Seven Dialysers","volume":"20","author":"Franssen","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00240-005-0004-6","article-title":"Calcium Oxalate Saturation in Dialysis Patients with and without Primary Hyperoxaluria","volume":"34","author":"Ogawa","year":"2006","journal-title":"Urol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/ajt.12535","article-title":"Auxiliary Liver Transplant Is an Ineffective Treatment of Primary Hyperoxaluria","volume":"14","author":"Trotter","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00467-021-05043-6","article-title":"Transplantation Outcomes in Patients with Primary Hyperoxaluria: A Systematic Review","volume":"36","author":"Metry","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ekir.2021.11.006","article-title":"Long-Term Transplantation Outcomes in Patients with Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry","volume":"7","author":"Metry","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.urology.2014.11.018","article-title":"Surgical Management of Stone Disease in Patients with Primary Hyperoxaluria","volume":"85","author":"Carrasco","year":"2015","journal-title":"Urology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1053\/j.ajkd.2021.07.018","article-title":"Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review","volume":"79","author":"Demoulin","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e31194","DOI":"10.1097\/MD.0000000000031194","article-title":"Which Is the Best Way for Patients with Ureteral Obstruction? Percutaneous Nephrostomy versus Double J Stenting","volume":"101","author":"Zhang","year":"2022","journal-title":"Medicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/end.2019.0455","article-title":"Endourologic Management (PCNL, URS, SWL) of Stones in Solitary Kidney: A Systematic Review from European Association of Urologists Young Academic Urologists and Uro-Technology Groups","volume":"34","author":"Pietropaolo","year":"2020","journal-title":"J. Endourol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00345-017-2030-8","article-title":"Treatment Selection for Urolithiasis: Percutaneous Nephrolithomy, Ureteroscopy, Shock Wave Lithotripsy, and Active Monitoring","volume":"35","author":"Desai","year":"2017","journal-title":"World J. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1089\/end.2006.20.870","article-title":"Predictors of Clinical Significance of Residual Fragments after Extracorporeal Shockwave Lithotripsy for Renal Stones","volume":"20","author":"Madbouly","year":"2006","journal-title":"J. Endourol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.ki.5000162","article-title":"Oxalobacter Sp. Reduces Urinary Oxalate Excretion by Promoting Enteric Oxalate Secretion","volume":"69","author":"Hatch","year":"2006","journal-title":"Kidney Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"G461","DOI":"10.1152\/ajpgi.00434.2010","article-title":"Enteric Oxalate Elimination Is Induced and Oxalate Is Normalized in a Mouse Model of Primary Hyperoxaluria Following Intestinal Colonization with Oxalobacter","volume":"300","author":"Hatch","year":"2011","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00467-019-04463-9","article-title":"Oxalobacter Formigenes Treatment Combined with Intensive Dialysis Lowers Plasma Oxalate and Halts Disease Progression in a Patient with Severe Infantile Oxalosis","volume":"35","author":"Pape","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ndt\/gfaa135","article-title":"Effects of Oxalobacter Formigenes in Subjects with Primary Hyperoxaluria Type 1 and End-Stage Renal Disease: A Phase II Study","volume":"36","author":"Hoppe","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00467-022-05591-5","article-title":"ePHex: A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate Long-Term Efficacy and Safety of Oxalobacter Formigenes in Patients with Primary Hyperoxaluria","volume":"38","author":"Ariceta","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.kint.2019.06.011","article-title":"Stiripentol for the Treatment of Primary Hyperoxaluria and Calcium Oxalate Nephropathy","volume":"97","author":"Wyatt","year":"2020","journal-title":"Kidney Int."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI99822","article-title":"Stiripentol Protects against Calcium Oxalate Nephrolithiasis and Ethylene Glycol Poisoning","volume":"129","author":"Huguet","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00467-020-04585-5","article-title":"Stiripentol Fails to Lower Plasma Oxalate in a Dialysis-Dependent PH1 Patient","volume":"35","author":"Kempf","year":"2020","journal-title":"Pediatr. Nephrol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfaa068","article-title":"Is Stiripentol Truly Effective for Treating Primary Hyperoxaluria?","volume":"14","author":"Hoppe","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.juro.2012.12.004","article-title":"Lanthanum Carbonate Inhibits Intestinal Oxalate Absorption and Prevents Nephrocalcinosis after Oxalate Loading in Rats","volume":"189","author":"Robijn","year":"2013","journal-title":"J. Urol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ekir.2024.11.020","article-title":"A Targeted Release Capsule of Lanthanum Carbonate: A New Efficient Cheap Treatment for Primary Hyperoxalurias","volume":"10","author":"Uytterhoeven","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/iju5.12296","article-title":"Lanthanum Carbonate to Control Plasma and Urinary Oxalate Level in Type 1 Primary Hyperoxaluria?","volume":"4","author":"Pozdzik","year":"2021","journal-title":"IJU Case Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11255-019-02098-1","article-title":"ALLN-177, Oral Enzyme Therapy for Hyperoxaluria","volume":"51","author":"Lingeman","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"EVIDoa2100053","DOI":"10.1056\/EVIDoa2100053","article-title":"Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria","volume":"1","author":"Lieske","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1002\/ctm2.261","article-title":"Knockdown of Lactate Dehydrogenase by Adeno-Associated Virus-Delivered CRISPR\/Cas9 System Alleviates Primary Hyperoxaluria Type 1","volume":"10","author":"Zheng","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymthe.2024.10.003","article-title":"Efficient and Safe in Vivo Treatment of Primary Hyperoxaluria Type 1 via LNP-CRISPR-Cas9-Mediated Glycolate Oxidase Disruption","volume":"33","author":"Jiang","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.kint.2020.04.049","article-title":"CRISPR\/Cas9-Mediated Metabolic Pathway Reprogramming in a Novel Humanized Rat Model Ameliorates Primary Hyperoxaluria Type 1","volume":"98","author":"Zheng","year":"2020","journal-title":"Kidney Int."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"eadt9694","DOI":"10.1126\/sciadv.adt9694","article-title":"Preclinical Evaluation of AGT mRNA Replacement Therapy for Primary Hyperoxaluria Type I Disease","volume":"11","author":"Yang","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1681\/ASN.0000000690","article-title":"Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment","volume":"36","author":"Cox","year":"2025","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/940\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:36:37Z","timestamp":1769506597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":91,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15030940"],"URL":"https:\/\/doi.org\/10.3390\/jcm15030940","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}